JPH05238996A - Ｎ−アルキル−３−フェニル−３−（２−ハロ置換フェノキシ）プロピルアミン類 - Google Patents

Ｎ−アルキル−３−フェニル−３−（２−ハロ置換フェノキシ）プロピルアミン類

Info

Publication number
JPH05238996A
JPH05238996A JP4256333A JP25633392A JPH05238996A JP H05238996 A JPH05238996 A JP H05238996A JP 4256333 A JP4256333 A JP 4256333A JP 25633392 A JP25633392 A JP 25633392A JP H05238996 A JPH05238996 A JP H05238996A
Authority
JP
Japan
Prior art keywords
phenyl
norepinephrine
acid
compounds
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP4256333A
Other languages
English (en)
Japanese (ja)
Inventor
Donald R Gehlert
ドナルド・リチャード・ゲーラート
David W Robertson
デイビッド・ウェイン・ロバートソン
David Taiwai Wong
デイビッド・タイワイ・ウォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH05238996A publication Critical patent/JPH05238996A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/29—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP4256333A 1991-09-27 1992-09-25 Ｎ−アルキル−３−フェニル−３−（２−ハロ置換フェノキシ）プロピルアミン類 Withdrawn JPH05238996A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/766,993 US5281624A (en) 1991-09-27 1991-09-27 N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US766993 1991-09-27

Publications (1)

Publication Number Publication Date
JPH05238996A true JPH05238996A (ja) 1993-09-17

Family

ID=25078150

Family Applications (2)

Application Number Title Priority Date Filing Date
JP4256333A Withdrawn JPH05238996A (ja) 1991-09-27 1992-09-25 Ｎ−アルキル−３−フェニル−３−（２−ハロ置換フェノキシ）プロピルアミン類
JP25632792A Expired - Fee Related JP3256291B2 (ja) 1991-09-27 1992-09-25 Ｎ−アルキル−３−フェニル−３−（２−アルキルチオフェノキシ）プロピルアミン類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP25632792A Expired - Fee Related JP3256291B2 (ja) 1991-09-27 1992-09-25 Ｎ−アルキル−３−フェニル−３−（２−アルキルチオフェノキシ）プロピルアミン類

Country Status (23)

Country Link
US (1) US5281624A (2)
EP (1) EP0534756A3 (2)
JP (2) JPH05238996A (2)
KR (1) KR100221180B1 (2)
CN (1) CN1033580C (2)
AT (1) ATE124934T1 (2)
AU (1) AU655075B2 (2)
BR (2) BR9203743A (2)
CA (2) CA2079161C (2)
CZ (1) CZ281817B6 (2)
DE (1) DE69203424T2 (2)
FI (1) FI111250B (2)
HU (1) HU215519B (2)
IL (1) IL103277A (2)
MX (1) MX9205433A (2)
MY (1) MY108304A (2)
NO (1) NO178109C (2)
NZ (1) NZ244460A (2)
RU (1) RU2057120C1 (2)
SK (1) SK280480B6 (2)
TW (1) TW249225B (2)
YU (1) YU87192A (2)
ZA (1) ZA927240B (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506872A (ja) * 2006-10-16 2010-03-04 アルキミカ ソシエタ ア レスポンサビリタ リミタータ アリールオキシプロピルアミンおよびヘテロアリールオキシプロピルアミンを合成する方法
JP2020536941A (ja) * 2017-10-16 2020-12-17 エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. 疼痛及び疼痛に関連する状態を治療するためのプロパンアミン誘導体

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071970A (en) * 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US7087765B2 (en) * 1995-06-07 2006-08-08 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
AU709704B2 (en) * 1995-07-24 1999-09-02 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
EP1069900B1 (en) * 1998-04-09 2005-08-10 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of neuropsychiatric disorders
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
HUP0200898A3 (en) 1999-04-06 2005-09-28 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
EP1188747B1 (en) 1999-05-24 2005-09-07 Mitsubishi Pharma Corporation Phenoxypropylamine compounds
ES2246488T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC Reboxetina para tratar la migraña.
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
PT1455770E (pt) * 2001-11-30 2007-09-06 Lilly Co Eli Uso de inibidores de reabsorção da norepinefrina para o tratamento dos transtornos de tiques.
CA2467802A1 (en) * 2001-12-11 2003-06-19 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
ATE365554T1 (de) * 2003-04-04 2007-07-15 Dynogen Pharmaceuticals Inc Methode zur behandlung von erkrankungen der unteren harnwege
US20060241188A1 (en) * 2003-08-27 2006-10-26 Elililly And Company Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors
CN1889940A (zh) * 2003-12-12 2007-01-03 伊莱利利公司 热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
CN113121394B (zh) * 2019-12-30 2022-11-08 中国药科大学 一种苯氧乙酸类衍生物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313896A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Aryloxyphenylpropylamines
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4584404A (en) * 1974-01-10 1986-04-22 Eli Lilly And Company Substituted phenoxyphenylproply dimethylamines
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
ZA892517B (en) * 1988-04-08 1990-12-28 Lilly Co Eli Propanamine derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506872A (ja) * 2006-10-16 2010-03-04 アルキミカ ソシエタ ア レスポンサビリタ リミタータ アリールオキシプロピルアミンおよびヘテロアリールオキシプロピルアミンを合成する方法
JP2020536941A (ja) * 2017-10-16 2020-12-17 エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. 疼痛及び疼痛に関連する状態を治療するためのプロパンアミン誘導体

Also Published As

Publication number Publication date
NZ244460A (en) 1994-10-26
CA2079161A1 (en) 1993-03-28
HU9203051D0 (en) 1992-12-28
KR930005972A (ko) 1993-04-20
AU2537092A (en) 1993-04-01
KR100221180B1 (ko) 1999-09-15
RU2057120C1 (ru) 1996-03-27
HU215519B (hu) 1999-01-28
EP0534756A3 (en) 1993-06-16
FI111250B (fi) 2003-06-30
CZ290892A3 (en) 1993-04-14
NO923710D0 (no) 1992-09-24
JPH05201961A (ja) 1993-08-10
CA2079161C (en) 2004-02-17
FI924305L (fi) 1993-03-28
DE69203424D1 (de) 1995-08-17
BR9203743A (pt) 1993-04-20
YU87192A (sh) 1995-10-24
ZA927240B (en) 1994-03-22
IL103277A0 (en) 1993-02-21
MX9205433A (es) 1993-03-01
SK290892A3 (en) 2000-02-14
NO178109C (no) 1996-01-24
CA2079162A1 (en) 1993-03-28
CN1071416A (zh) 1993-04-28
US5281624A (en) 1994-01-25
SK280480B6 (sk) 2000-02-14
BR1100384A (pt) 1999-08-31
CN1033580C (zh) 1996-12-18
EP0534756A2 (en) 1993-03-31
CZ281817B6 (cs) 1997-02-12
MY108304A (en) 1996-09-30
JP3256291B2 (ja) 2002-02-12
AU655075B2 (en) 1994-12-01
HUT65375A (en) 1994-05-02
NO178109B (no) 1995-10-16
ATE124934T1 (de) 1995-07-15
DE69203424T2 (de) 1996-01-11
FI924305A0 (fi) 1992-09-25
NO923710L (no) 1993-03-29
IL103277A (en) 1997-11-20
TW249225B (2) 1995-06-11

Similar Documents

Publication Publication Date Title
JP3256291B2 (ja) Ｎ−アルキル−３−フェニル−３−（２−アルキルチオフェノキシ）プロピルアミン類
FI77018B (fi) Analogifoerfarande foer framstaellning av antidepressivt aktiv (-)-enantiomer av n-metyl-n-/3-(2-metylfenoxi) -3-fenylpropyl/amin och dess farmaceutiskt godtagbara salt.
PT86389B (pt) Processo para a preparacao de 3-ariloxi-propanaminas 3-substituidas
JPS62230722A (ja) 肥満および／または関連状態の治療剤
US4584404A (en) Substituted phenoxyphenylproply dimethylamines
US20030119851A1 (en) 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands
DE68922277T2 (de) Fluoxetin-Analogon.
RU2001911C1 (ru) Способ получени замещенных 1,2,3,4-тетрагидронафталинов или их фармацевтически приемлемых аддитивных солей кислоты
JPH02235A (ja) セロトニンおよびノルエピネフリン摂取阻害剤
JP2000034230A (ja) 含硫黄抗真菌剤
EP0537915B1 (en) N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines as norepinephrine inhibitors
DE3879402T2 (de) Selektive sertonin-aufnahme-inhibitoren.
EP0591581B1 (en) N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines
CA1198735A (en) Esters of 2-thenoylmercaptopropionylglycine with substituted hydroxybenzenes, process for their preparation and pharmaceutical compositions containing same
US4065501A (en) Basic enol ether and acid addition salts thereof
JP3681770B2 (ja) 老年性痴呆症又はアルツハイマー病治療剤
JPH06256189A (ja) アセタミド−アルギン酸配合体を有効成分とする抗潰瘍薬
JP2000034285A (ja) 抗真菌剤
JPH01265024A (ja) ２―ピリジル酢酸誘導体およびそれを含む医薬

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 19991130